Introduction
============

Prostate cancer (PCa) remains the third leading malignancy engendering mortality among men globally. Metastasis is the leading cause for the death of PCa patients, the 5-year survival rate is merely 29% [@B1].During metastasis process, cancer cells invade into neighboring tissue or lymphatic circulation, blood circulation and survive to form distant metastases[@B2]. To better understand the mechanistic basis of cancer metastasis, identifying the critical molecules involved in metastasis is necessary.

HCRP-1 is identified as a member of the human endosomal sorting complex required for transport-1 (ESCRT-I) families. It can bind and sort of ubiquitinated receptors to intraluminal vesicles of MVBs (multivesicular bodies), and then degrade them in lysosomes [@B3], [@B4]. HCRP-1 has been implicated in cancer progression. HCRP-1 was firstly found significantly lost in hepatocellular cell carcinoma (HCC) tissues but abundant in normal liver tissues [@B5]. Loss of HCRP-1 is associated with the activation of EGFR (epidermal growth factor receptor), which exerts an influence on EGFR prognosis. Down-regulated HCRP-1 leads to invasive phenotype of ovarian cells and tumor growth *in vivo* [@B6]. In addition, it is proved to be of adverse prognostic significance that oropharyngeal squamous cell carcinoma (OOSCC) patients with less HCRP-1 expression received preoperative chemoradiotherapy [@B7]. Our previous study showed that HCRP-1 was decreased in colorectal cancer (CRC). Reduced HCRP-1 expression caused CRC cancer cells anoikis resistance and surviving cells formed metastasis and resulted in poor prognosis in CRC [@B8]. These studies indicate that HCRP-1 acts as a tumor suppressor in cancer progression.

In this study, we investigated the relationship between HCRP-1 expression and clinicopathologic features by PCa tissue microarray (TMA). Furthermore, we showed a role for HCRP-1 in regulation of migration, invasion and angiogenesis in human PCa cells. Lastly, our data provided a profound understanding of novel HCRP-1 - Src/FAK signaling in promoting PCa migration, invasion and angiogenesis.

Material and Methods
====================

Patients and samples
--------------------

A PCa TMA was purchased from Shanghai OUTDO Biotech CO., LTD. (China). Tumors were staged and graded based on 2010 revised TNM system and WHO criteria, respectively [@B9]. The clinicopathological characteristics of TMA are described in Table [1](#T1){ref-type="table"}. Moreover, 90 cases of PCTs were provided.

Antibodies and Reagents
-----------------------

Rabbit monoclonal antibodies to EGFR, p-EGFR (Tyr1173), FAK, p-FAK (Tyr397), Src, p-Src (Tyr416) and CD31 were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibody HCRP-1 was from Proteintech (Wuhan, China). Antibodies against GAPDH were from Santa Cruze (CA, USA). The p-FAK inhibitor, FAK inhibitor 14 and Src inhibitor, PP2 were from Abcam (Cambridge, MA, USA).Cycloheximide (CHX) were ordered from Sigma (Shanghai, China).

Immunohistochemistry
--------------------

The TMA slide or tissues were incubated with primary antibodies overnight at 4°C, and visualization with diaminobenzidine (DAB; sigma, Shanghai, China). The image was collected by light microscopy (Olympus BX-51 light microscope). The evaluation of HCRP-1 in TMA was performed as previously described [@B8].

Cell Culture
------------

Human PCa cell lines PC3 and LnCap were cultured in RPMI1640 medium enriched with 10% fetal calf serum (Invitrogen, Shanghai, China). Cells were cultured in a 37℃ humidified incubator with 95% air, 5% CO~2~.

Transfection and PC3 stable cell line generation
------------------------------------------------

HCRP-1 siRNA were ordered from GenePharma (Shanghai, China). The sequences are as follows: HCRP-1,5′-GACACUGUUUCUUCUUCAACA-3′. Transient transfections were performed using silentFect Lipid Reagent (Bio-Rad, Hercules, CA, USA) following the manufacturer\'s instructions. GFP-lentivirus-packing HCRP-1 shRNA vector (IBS, Shanghai, China) infectedPC3 cells for two days, and then screened out with 2 μg/ml puromycin (Sigma, Shanghai, China) for 14 days.

Angiogenesis assay
------------------

The medium from transfected PC3 and LnCap cells was collected and used as a conditioned medium. 2×10^4^ human umbilical vein endothelial cells in 100 μl conditioned medium were seeded in the Matrigel pre-coated 48-well plate. Three randomly chosen fields were selected to photograph the number of capillary-like tubes using a Nikon inverted microscope (Nikon, Japan).

Cell migration and invasion assay
---------------------------------

Cell migration and invasion assay were performed as described previously [@B10]. Modified two chamber plates with a pore size of 8 μm were employed. The transwell filter that inserts without Matrigel (BD Biosciences) coating was used for migration assay. The transwell filter that coated with Matrigel (BD Biosciences) was used for invasion assay.

Western blot analysis
---------------------

After transfection, cells were harvested and cell extracts were separated on SDS-polyacrylamide gel. The proteins were blotted on nitrocellulose membrane and incubated with appropriate primary antibodies overnight at 4°C. Secondary antibodies included horseradish peroxidase (HRP)-goat anti-mouse and HRP-goat anti-rabbit (ZSGB-BIO). Protein bands were detected by Tanon5200 automatic chemiluminescence imaging analysis system using ECL reagent (Tanon, shanghai, China).

Co-immunoprecipitation
----------------------

PC3 cells were lysed and the cell lysates were precleared with mouse normal IgG and protein G-agarose for 30 min. Then, HCRP-1 and HCRP-1-specific IgGs were incubated with the precleared mixture overnight. Then, the immunoprecipitates were washed with cold lysis buffer for five times and applied to Western blotting assay.

*In vivo* experimental metastasis models
----------------------------------------

Each group consists of eight male nude mice. 1.0×10^6^ shHCRP-1 stably expressed PC3 cells were injected with mice via tail vein. 8 weeks post-implantation, mice were euthanized and lung tissues were fixed in 10% formaldehyde. HE stained was applied for metastatic nodules. Bioluminescence imaging of the mice were analyzed using Xenogen IVIS200 imaging system (Xenogen Corp.). Animal experiments were performed following protocols approved by the Committee of Xuzhou Medical University for the Use and Care of Animals.

Subcutaneous *in vivo* experiments
----------------------------------

To explore tube formation *in vivo*, male nude mice were injected with 1.0×10^6^ shHCRP-1 stably expressed PC3 cells in 100 μl PBS/Matrigel (50:50) subcutaneously. The body weight was monitored and tumor volume was calculated by vernier caliper every day. 8 weeks after implantation, mice were euthanized and tumors were surgically removed and fixed in 10% formaldehyde for histology.

Statistical analysis
--------------------

We used SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL) for all analyses. Data are presented as means ± SD. Dunnett\'s t test (two-factor) was employed to evaluate differences within treatment groups. HCRP-1 staining in PCa TMA and clinicopathologic parameters was evaluated by χ^2^ test. A *P*-value equal to or \<0.05 was considered statistically significant.

Results
=======

The expression of HCRP-1 is reduced in human PCa
------------------------------------------------

To determine HCRP-1 expression in human PCa, we used TMA slide containing PCTs and paired NTs for immunohistochemistry staining. Data showed that HCRP-1 was mainly localized in the cytoplasmic (Fig. [1](#F1){ref-type="fig"}A). In NTs, strong cytoplasmic staining was observed in normal prostate epithelia. 76.7% (69 of 90 cases) patients showed positive HCRP-1 staining. In PCTs, strong expression of HCRP-1 was recorded in 42.2% (38 of 90 cases) (Fig. [1](#F1){ref-type="fig"}B). The expression of HCRP-1 was significant reduced in the PCTs when compared with NTs (*P*\<0.001, χ^2^ test).

HCRP-1 expression with clinicopathological parameters
-----------------------------------------------------

We next investigated the correlation between HCRP-1 staining and clinicopathological features in PCa (Table [1](#T1){ref-type="table"}). We found that loss of HCRP-1 was significantly correlated with histological grade when compared I-II with III-IV (*P*\<0.05, Fig. [1](#F1){ref-type="fig"}C). Since TNM stage is a critical prognostic marker for cancer patients, we examined whether reduced HCRP-1 expression correlates with TNM stage. Data displayed that HCRP-1 expression was dramatically reduced in late TNM stages (III-IV) when compared with early stages (I-II) (*P*\<0.05, Fig. [1](#F1){ref-type="fig"}D). Moreover, decreased HCRP-1 expression was significantly decreased in high gleason score (\>7) (*P*\<0.05, Fig. [1](#F1){ref-type="fig"}E). However, there is no significant correlation between HCRP-1 expression andage.

Loss of HCRP-1 promotes PCa cells migration, invasion and angiogenesis
----------------------------------------------------------------------

To investigate the effect of HCRP-1 on cell phenotypes, we transiently transfected PC3 and LnCap cells with control siRNA and HCRP-1 siRNA to inhibit HCRP-1 protein levels (Fig. [2](#F2){ref-type="fig"}A and B). We then assessed whether alteration of HCRP-1 affected the malignant characteristics of the prostate cancer cell lines. We first detected the migration ability of cancer cells and data showed that the thecapacity of cell migration was drastically promoted after knockdown of HCRP-1 expression (Fig. [2](#F2){ref-type="fig"}C and D). The results from the cell invasion assay were corresponded with the cell migration assay (Fig. [2](#F2){ref-type="fig"}E and F). Moreover, we evaluated the effect of decreased HCRP-1 expression on angiogenic potential of human PCa cells. As shown in Figure [2](#F2){ref-type="fig"}G and H, the number of HUVECs formed tubular structures was obviously increased in conditioned medium from HCRP-1 knockdown cancer cells.

HCRP-1 regulates Src/FAK signaling pathway in PCa cells
-------------------------------------------------------

HCRP-1 mediates the internalization and degradation of EGFR. We detected the half-life of EGFR to clarify whether the stability of EGFR exerted influence oncells metastasis phenotypes in HCRP-1 knockdown PCa cells. We observed that the stability was sustained in both two cell lines (Fig. [3](#F3){ref-type="fig"}A, B). Ineffective receptor sorting could lead to phosphorylated EGFR receptor accumulation in cancer cells. We explored that whether HCRP-1 might regulate EGFR activation. Our data showed that phosphorylation of EGFR remains unchanged (Fig. [3](#F3){ref-type="fig"}C). It has been well studied that Src/FAK signaling plays an important role in cell migration, invasion and angiogenesis. Therefore, we detected the phosphorylation of Src and FAK in cells transfected with control siRNA and HCRP-1 siRNA. The results showed that knockdown of HCRP-1 expression induced Src and FAK phosphorylation (Fig. [3](#F3){ref-type="fig"}C). We further performed immunoprecipitation experiments in PC3 cells to investigate the interaction of HCRP-1 and Src. The results showed that HCRP-1 or Src immunoprecipitates were associated with endogenous Src or HCRP-1 protein (Fig. [3](#F3){ref-type="fig"}D), confirming the specific association between HCRP-1 and Src. There results suggest that HCRP-1 may regulate Src/FAK signaling pathway via interaction of HCRP-1 and Src.

Inhibition of HCRP-1 promotes cells migration, invasion and angiogenesis through Src/FAK signaling pathway
----------------------------------------------------------------------------------------------------------

To further investigate whether HCRP-1 regulates cells migration, invasion and angiogenesis through Src/FAK signaling pathway, we firstly added the Src-specific inhibitor, PP2 (5 μM), into PCa cells that was transfected with HCRP-1 siRNA. Western blot data indicated that PP2 obviously suppressed Src and FAK phosphorylation in HCRP-1-knockdown cells (Fig. [4](#F4){ref-type="fig"}A). The migration and invasion cells were obviously decreased in HCRP-1-deficient cells treated with PP2 (Fig. [4](#F4){ref-type="fig"}B). In addition, the angiogenesis of PC cells was determined by endothelial cell tube formation assay. The number of HUVECs formed tubular structures was obviously increased in conditioned medium from HCRP-1 knockdown cancer cells. However, this induction was suppressed by Src-specific inhibitor PP2 (Fig. [4](#F4){ref-type="fig"}C).

To further explore the functions of Src/FAK signaling pathway in regulating cell migration, invasion and angiogenesis by HCRP-1, we also employed FAK-specific inhibitor 14 (100 mM) to inhibit FAK phosphorylation. Our data testified to that FAK-specific inhibitor 14 lead to the reduction of FAK phosphorylation which was induced by knockdown of HCRP-1 (Fig. [5](#F5){ref-type="fig"}A). The migration and invasion abilities were suppressed by treatment of PC3 and LnCap cells with FAK-specific inhibitor 14 (Fig.[5](#F5){ref-type="fig"}B). Subsequently, we also found that angiogenesis ability was inhibited by FAK-specific inhibitor 14 (Fig.[5](#F5){ref-type="fig"}C). These data suggest that Src/FAK signaling is involved in the promotion of PCa cancer cells migration, invasion and angiogenesis induced by depletion of HCRP-1.

Depletion of HCRP-1promoted prostate cancer tumorigenesis, angiogenesis and metastasis *in vivo*
------------------------------------------------------------------------------------------------

To evaluate a role for HCRP-1 in tumor metastasis *in vivo*, an experimental metastasis assay was performed with luciferase-expressing PC3 cells infected with scrambled control or shRNA against HCRP-1. Two months later, a statistical difference was noticed that PCa cells with the HCRP-1-knockdown had a higher signal in the lungs compared with the scrambled control (Fig. [6](#F6){ref-type="fig"}A). Then, the mice were executed to analyze the lung metastasis status. As shown in Fig. [6](#F6){ref-type="fig"}B-D, more multiple large metastatic foci in lung were observed in the samples containing PC3-shHCRP-1 cells. Immunohistochemistry staining of metastatic nodules in lungs showed that p-Src and p-FAK expression in the HCRP-1-knockdown group was high compared with the control group (Fig. [6](#F6){ref-type="fig"}E). Next, we employed xenograft models using nude mice subcutaneously transplanted with PC3 cells that were mock treated or depleted of HCRP-1 to evaluate the effect of HCRP-1 on tumor growth *in vivo*. As shown in Fig. [6](#F6){ref-type="fig"}F and G, HCRP-1 knockdown cells formed bigger tumors than the control. Also, the expression levels of HCRP-1, p-Src, p-FAK and CD31 were high in the HCRP-1 knockdown subcutaneous tumors (Fig. [6](#F6){ref-type="fig"}H). Next, these findings provided compelling evidence for the ability of HCRP-1 to confer tumorigenesis and metastasis *in vivo*.

Discussion
==========

In our work, we provide a set of data suggesting critical roles for HCRP-1 in PCa angiogenesis and metastasis. First, it was found that in human PCa patients, low HCRP-1 expression correlates/is associated with/related to clinicopathologic parameters, revealing HCRP-1 as a novel candidate tumor-suppressor gene in PCa (Fig. [1](#F1){ref-type="fig"}). Second, evidence was presented, demonstrating a supporting role for HCRP-1 in prostate cancer cell migration, invasion and angiogenesis (Fig. [2](#F2){ref-type="fig"}). Third, HCRP-1 was shown to regulate cell migration, invasion and angiogenesis through interacting with Src/FAK signaling (Fig. [3](#F3){ref-type="fig"}-[5](#F5){ref-type="fig"}). Finally, the results of mouse xenograft experiments revealed a role for HCRP-1 in promoting prostate cancer angiogenesis and metastasis *in vivo* (Fig. [6](#F6){ref-type="fig"}).

The vital role for HCRP-1 expression in cancer development has been reported in several malignancies, such as ovarian cancer, HCC and breast cancer [@B5], [@B6], [@B11]. Low HCRP-1 mRNA expression was independently associated with shorter disease-free survival in HCC and breast cancer [@B5]. We previous found that RCC patients were significantly correlated with decreased overall survival only in tumors with low or missing HCRP-1 expression [@B10]. In PCTs, we identified decreased expression of HCRP-1 protein in cancer tissues. Moreover, we explored the correlation between HCRP-1 staining and clinicopathological features. Our results displayed that loss expression of HCRP-1 occurred in most of PCa patients, and this reduced expression had significantly correlation with histological grade, TNM stage and Gleason score. Collectively, these observations suggest that HCRP-1 have a potential effect on PCa progression and metastasis.

Distant metastasis has been reported as the main cause of death in PCa patients [@B12]. A critical step in cancer metastasis is the migration and invasion of cancer cells [@B13]. Since the invasiveness of cancer cells depends on increased migratory and invasive properties, we explored the potential role of HCRP-1 in suppressing migration and invasion of PCa cells. Knockdown of HCRP-1 protein lead to significant induction and alteration of PCa cells migratory and invasive properties. Similarly, ablation of HCRP-1 obviously promoted tumor progression and metastasis *in vivo*.

Solid tumors growth and metastasis depends on angiogenesis, including PCa, which is the progression of forming new blood vessels from the existing network of capillaries [@B14]. Targeting angiogenesis is effective in cancer therapy not only because angiogenesis supplies oxygen and nutrients for the survival of cancer cells, but also provides the way for metastatic spread of these cancer cells [@B15]. Here, we showed that inhibition of HCRP-1 expression promoted tube formation of HUVECs induced by prostate cancer cells. *In vivo*, knockdown of HCRP-1 promoted CD31 expression in prostate tumors. These data revealed that angiogenesis serve as a crucial role in promoting cancer metastasis by knockdown of HCRP-1.

In order to further elucidate the mechanisms involved in HCRP-1-induced prostate cancer cell migration, invasion and angiogenesis, PC3 and LnCap cells were transfected with siRNA for HCRP-1, phosphorylation of Src and FAK was detected. We found that knockdown of HCRP-1 induced phosphorylation of Src and FAK. Src is a non-receptor tyrosine kinase, which is induced by various kinds of cellular signal molecules and has a great effect in regulating numerous processes, including cell growth, differentiation, adhesion and the migration signaling pathway [@B16], [@B17]. As an other non-receptor protein tyrosine kinase, FAK is widely expressed and regulats several biological processes, including cell adhesion, angiogenesis and migration [@B18], [@B19]. At the sites of cell-substratum focal adhesions, FAK can combine withSrc to form a dual-kinase complex[@B20], which coordinate cell behavior through regulating downstream pathways and molecules, including AKT, p38 and ERK kinase[@B21], [@B22]. Autophosphorylation of Src/FAK complexes is a critical event in cancer progression and metastasis [@B23]. Src/FAK pathway kinases in solid tumors have been viewed as an attractive target in cancer therapy. Inhibition of Src family kinase exerts effects on the tumor microenvironment [@B24], [@B25]. In our present study, the Src-specific inhibitor PP2 were used to abrogate the activation of Src, and the results showed that FAK activity and cells migration, invasion and angiogenesis were suppressed by PP2 in PC3 and LnCap cells. Additionally, FAK inhibitor 14 could inhibit the phosphorylation levels of Src and FAK. Combined with our results, we suggested that HCRP-1 knockdown might induce cell migration, invasion and angiogenesis by deregulating Src/FAK-associated signaling pathways in prostate cancer cells.

HCRP-1 is involved in binding and sorting of EGFR and the consequent degradation with lysosomes [@B4]. Src/FAK and EGFR converge on common downstream pathways [@B26], which exhibit antitumor activity in patients with advanced NSCLC co-treated with inhibitors of both signaling pathways [@B27]. We detected the half-life of EGFR to elucidate whether EGFR stability exerted influence on Src/FAK pathway in HCRP ablation cells. The stability was sustained in both WT and HCRP-1 knockdown cancer cells. Next, we investigated the phosphorylation of EGFR and our data showed that reduced HCRP-1 expression did not change EGFR activity. We assumed that HCRP-1 could regulate Src/FAK signaling through other mechanism. As the ESCRT-I subunit, Tsg101 (tumor susceptibility gene101) deletion impaired Src-dependent activation of STAT3 and FAK, resulted in cell migration suppression [@B28]. Moreover, as other ESCRT-I subunit, Alix binds to Src at two points via SH2 (Src homology 2) and SH3 (Src homology 3) domains. Alix that binds to Src are typically phosphorylated by Src [@B29]. Therefore, we investigated the endogenous interaction of HCRP-1 and Src. We demonstrated that endogenous Src and HCRP-1 in untransfected cells were associated, suggests that the interaction between Src and HCRP-1 has physiological relevance. We supposed that the interaction of HCRP-1 and Src contributed to the regulation of Src activity.

In conclusion, we have established a vital role for HCRP-1 in PCa and our clinical analyses point the prospect of HCRP-1 as a potential molecular therapeutic target for highly aggressive prostate cancer. We also revealed that HCRP-1 regulated prostate cancer cell migration, invasion and angiogenesis. In mechanism, HCRP-1 may regulate Src/FAK signaling pathway through interaction with Src. Although more details still need to explore the functions of HCRP-1 in a physiologic condition, our data uncover the importance of HCRP-1 in PCa progression and metastasis.
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![**Correlation between HCRP-1 expression and clinicopathologic parameters in prostate cancer. A.** Representative immunohistochemical photographs were taken at different magnifications in NTs and PCTs (Top panel ×100, bottom panel ×400).**B.** Compared with that in the tumor adjacent normal prostate tissue, the overall expression level of HCRP-1 in the prostate cancer tissues was significantly lower (*P*\<0.001, χ^2^ test). **C.** Decreased HCRP-1 expression was correlated with histological grade (*P*\<0.05, χ2 test, comparing I-II versus III-IV). **D.** Decreased HCRP-1 expression was correlated with TNM stage (*P*\<0.05, χ2 test, comparing T1-2 versus T3-4). **E.** Decreased HCRP-1 expression was correlated with Gleason score (*P*\<0.05, χ2 test, comparing≤7 versus \>7).](ijbsv16p0342g001){#F1}

![**Effect of the reduction in HCRP-1 expression on the abilities of cell migration, invasion and angiogenesis *in vitro*. A,B.** Forty-eight hours after transfection, the expression of HCRP-1 in the PC3 and LnCap cells was evaluated by western blotting GAPDH was used as an internal control. **C-F.** Cell migration and matrigel cell invasion assays were performed in PC3 and LnCap cells after transfection, respectively. Representative fields of migrating or invading cells on the membrane (magnification, ×200). **G,H.** Representative pictures were taken in situ for tube formation in the supernatant of PC3 and LnCap cells transduced with siRNA foe HCRP-1 or control. The data are presented as mean±SD for triplicate determinations. \*\*\* *P*\<0.001.](ijbsv16p0342g002){#F2}

![**Endogenous interaction of HCRP-1 and Src contributes to Src/FAK signaling pathway. A,B.** Cells were treated CHX for 0, 0.5 h, 1h, 2h after transfected with si-HCRP-1 or control siRNA for 48 h, lysates obtained from these cells were submitted to Western blot detection for the protein expression of EGFR. **C.** Activities of EGFR, Src and FAK were determined by using Western blot analysis with antibodies specific for total and phosphorylated forms of EGFR, Src and FAK in silencing of HCRP-1 and control group for both PC3 and LnCap cell lines. **D.** Src were coprecipitated with HCRP-1 in whole-cell lysates of PC3 cells.](ijbsv16p0342g003){#F3}

![**Inhibition of Src activation blocked HCRP-1-induced cell migration, invasion and angiogenesis. A.** PC3 and LnCap cells were pretreated with HCRP-1 siRNA and the Src inhibitor, PP2. The whole cell lysates were analyzed for the protein levels of p-Src, Src, p-FAK, FAK and GAPDH by Western blot. **B.** Cell migration and Matrigel cell invasion were evaluated after HCRP-1 siRNA treatment and treatment with PP2 (5 μM). Representative fields of migrating or invading cells on the membrane (magnification, ×200). **C.** Tube formation was explored in the supernatant of PC3 and LnCap cells. The data are presented as mean±SD for triplicate determinations. \**P*\<0.05 versus siCtrl group;^\#^*P*\<0.05 versus siHCRP-1 group.](ijbsv16p0342g004){#F4}

![**Inhibition of FAK activation blocked HCRP-1-induced cell migration, invasion and angiogenesis. A.** PC3 and LnCap cells were pretreated with HCRP-1 siRNA and the FAK inhibitor, FAK inhibitor 14(200mM). The whole cell lysates were analyzed for the protein levels of p-Src, Src, p-FAK, FAK and GAPDH by Western blot. **B.** Cell migration and Matrigel cell invasion were evaluated after HCRP-1 siRNA treatment and treatment with FAK inhibitor 14. Representative fields of migrating or invading cells on the membrane (magnification, ×200).**C.** Tube formationwas explored in the supernatant of PC3 and LnCap cells. The data are presented as mean±SD for triplicate determinations. \**P*\<0.05 versus siCtrl group;^\#^*P*\<0.05 versus siHCRP-1 group.](ijbsv16p0342g005){#F5}

![**Loss of HCRP-1 induces tumor metastasis and angiogenesis *in vivo*. A.** PC cells were stably transfected with shHCRP-1 lentivirus. Bioluminescence imaging of Balb/c mice were intravenously injected with PC cells stably expressed shHCRP-1. **B.** Number of metastatic nodules injected with PC cells stably transfected with HCRP-1 lentivirus compared with the control groups. Metastatic nodules were highlighted by arrows. **C.** H&E staining sections of lungs 2 months after injection of HCRP-1KD-PC3 cell lines in BALB/c nude mouse through tail vein. **D.** Number of lung metastatic nodules was counted under a dissecting microscope. **E.** IHC detection of HCRP-1, p-Src and p-FAK protein expression in metastatic nodules. **F,G.** HCRP-1KD-PC3 cells were subcutaneously injected into BALB/c nude mice (n = 5, for each experimental group), and 8 weeks later, the xenograft tumors were peeled off and weighted. The tumor weights are presented as the means ± S.D. \*\**P*\<0.01. **H.** IHC detection of HCRP-1, p-Src and p-FAK protein expression in xenograft tumors formed by PC3-shCtrl/shHCRP-1 cells in BALB/c nude mice.](ijbsv16p0342g006){#F6}

###### 

HCRP-1 staining and patients clinicopathological characteristics.

  Variables                   HCRP-1 staining                    
  --------------------------- ----------------- ----------- ---- ---------
  **Cancer cases**            52 (57.8)         38 (42.2)   90   \<0.001
  **Latero-cancer tissue**    21 (23.3)         69 (76.7)   90   
  **Age**                     0.805                              
  ≤ 70 years                  26 (50.1)         18 (40.9)   44   
  \>70 years                  26 (56.5)         20 (43.5)   46   
  **Histopathologic Grade**   0.014                              
  G1-2                        13 (40.6)         19 (59.4)   32   
  G3-4                        39 (67.2)         19 (32.8)   58   
  **Gleason score**           0.045                              
  ≤ 7                         14 (43.8)         18 (56.2)   32   
  \>7                         38 (65.5)         20 (34.5)   58   
  **TNM stage**               0.022                              
  I-II                        29 (49.2)         30 (50.8)   59   
  III-IV                      23 (74.2)         8 (25.8)    31   

\**P* values are from χ2 test
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